Chief Operations Officer
Dr. Sabine Daugelat joined ITM as Chief Operations Officer of ITM’s clinical development in July 2021. She has over 18 years’ experience in the pharmaceutical and biotechnology industry.
Prior to joining ITM, Dr. Daugelat was Executive Director, Head of Project Leadership at Pieris Pharmaceuticals where she was responsible for strategic and operational oversight of all Anticalin® drug discovery and drug development projects. Preceding that, Dr. Daugelat served as Senior Global Program Team Director at Sandoz Biopharmaceuticals. In this position, she developed a number of biosimilars including oncology and immunology drugs such as Zessly® (biosimilar infliximab) which was developed with an external Alliance Partner and secured approval by the European Commission. Before her tenure at Sandoz, Dr. Daugelat held various positions at Novartis Pharma Clinical Operations.
She holds a PhD in Immunology from the University of Ulm.